53.32 0.00 (0.00%)
After hours: 4:17PM EST
|Bid||53.27 x 1000|
|Ask||53.29 x 1100|
|Day's Range||53.06 - 54.83|
|52 Week Range||39.11 - 68.30|
|Beta (3Y Monthly)||1.52|
|PE Ratio (TTM)||666.50|
|Earnings Date||Feb 19, 2020 - Feb 24, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||67.43|
Is Emergent Biosolutions Inc (NYSE:EBS) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent BioSolutions Inc. (EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate across a series of dosing regimens. The interim analysis has shown that after the first dose is administered, up to 98% of study participants produced a neutralizing antibody response against the chikungunya virus (CHIKV) within seven days after vaccination.
Emergent BioSolutions Inc. (EBS) today outlined its growth strategy over the next five years and announced its 2024 financial and operational goals during the company’s Analyst and Investor Day held in New York City. Emergent’s senior management shared their vision for continuing to build leadership positions in select public health threat markets and contract development and manufacturing (CDMO), leveraging the company’s unique set of assets, and realizing sustained financial performance and shareholder value creation.
GAITHERSBURG, Md., Nov. 18, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) will be hosting an analyst and investor day on November 21, 2019 from 8:00 AM EST to 2:00 PM EST in.
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 92.06% and 14.49%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Q3 2019 performance above guidance Full year 2019 financial forecast reaffirmed GAITHERSBURG, Md., Nov. 06, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial.
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
GAITHERSBURG, Md., Oct. 21, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the company will host an analyst and investor day on November 21, 2019 in New.
Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.
Yahoo Finance Premium members have access to the full 30-stock Argus Focus List. Activision creates video games. The company’s top game franchises include “Call of Duty,” “Diablo,” and “World of Warcraft.” Activision acquired King Digital Entertainment, the producer of the “Candy Crush” mobile puzzle game, in February 2016.
Emergent BioSolutions Inc. (EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME, designation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) during its September meeting. The PRIME scheme is designed to enhance support for the development of medicines that target an unmet medical need and that may offer a major therapeutic advantage over existing treatments, or benefit patients without preventative or treatment options.
GAITHERSBURG, Md., Oct. 09, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the.
Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.
Emergent BioSolutions Inc. (EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), U.S. Department of Health and Human Services, valued at approximately $6.3 million over two years, for the continued development of AP007, the company’s sustained-release nalmefene formulation for the treatment of addiction in opioid use disorder (OUD). AP007 is an extended-release formulation of nalmefene, an opioid receptor antagonist, intended to continually release an effective dose of nalmefene for up to three months and to be administered through intramuscular injection.
GAITHERSBURG, Md., Sept. 26, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Cantor.
Emergent BioSolutions Inc. (EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing diazepam (5 mg/mL) to treat nerve agent-induced seizures. Emergent’s device is being designed for intramuscular buddy-administration for use in military environments and for civilian emergencies. Doug White, SVP and devices business unit head at Emergent BioSolutions, stated, “Emergent is pleased with this follow-on contract, which expands our opportunities to serve the needs of the Department of Defense (DoD) for modern and reliable auto-injectors to protect our military personnel against nerve agents.
Emergent Biosolutions Inc (NYSE: EBS ) Tuesday announced a follow-on U.S. government contract for its smallpox vaccine, ACAM2000. There had been widespread investor concern around the delay in this contract, ...